EUVIMEDEUVIMED entdecken
Crossref

Clinical Implications of Genetic Profiling, Polygenic Risk Scores, LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease (ASCVD) – What is New?

David KL Quek

ASEAN Heart Journal · 2021

DOI: 10.31762/ahj2130.0101 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ASEAN Heart Journal, 2021. Verfasst von David KL Quek.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Elevated levels of circulating Low-density lipoprotein (LDL) is now considered as the predominant putative cause of Atherosclerotic Cardiovascular Disease (ASCVD) 1 We now recognise that LDL-cholesterol is central to the atherosclerotic process.The Lipid-Atherosclerosis hypothesis has been well established.Yet there is confusion and controversy as to its causative role with many physicians still implying that inflammatory processes may play a bigger role. 2

Zitieren

APA

Quek, D. K. (2021). Clinical Implications of Genetic Profiling, Polygenic Risk Scores, LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease (ASCVD) – What is New?. ASEAN Heart Journal. https://doi.org/10.31762/ahj2130.0101

Vancouver

Quek DK. Clinical Implications of Genetic Profiling, Polygenic Risk Scores, LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease (ASCVD) – What is New?. ASEAN Heart Journal. 2021. doi:10.31762/ahj2130.0101

BibTeX
@article{Quek2021,
  author = {Quek, David KL},
  title = {Clinical Implications of Genetic Profiling, Polygenic Risk Scores, LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease (ASCVD) – What is New?},
  journal = {ASEAN Heart Journal},
  year = {2021},
  doi = {10.31762/ahj2130.0101}
}
Kostenlos starten →